Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 26 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

27%

7 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

11 recruiting

Enrollment Performance

Analytics

Phase 4
5(41.7%)
N/A
4(33.3%)
Phase 3
2(16.7%)
Phase 1
1(8.3%)
12Total
Phase 4(5)
N/A(4)
Phase 3(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (26)

Showing 20 of 26 trials
NCT05871099Phase 3Recruiting

Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not

Role: collaborator

NCT07379281Recruiting

Evaluating the Efficacy of Neoadjuvant Chemotherapy Drugs Based on Organoid Technology

Role: collaborator

NCT07379255Recruiting

Evaluation of Postoperative Adjuvant Chemotherapy Efficacy for Bladder Cancer Based on Organoid Technology.

Role: collaborator

NCT07379268Recruiting

Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology.

Role: collaborator

NCT07051564Not ApplicableRecruiting

Clinical Study on the Treatment of Type 1 Diabetes With CNK-UT009 Cell Injection

Role: lead

NCT06916624Recruiting

Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma

Role: collaborator

NCT06916338Recruiting

Clinical Study of 18F-Labeled FAPI-04 in PET Imaging of Breast Cancer

Role: collaborator

NCT06728839Not ApplicableNot Yet Recruiting

Efficacy, Safety and Tolerability of Magnesium Sulfate With Low-volume Polyethylene Glycol for Colonoscopy Cleansing

Role: collaborator

NCT06683066Phase 1Recruiting

Study on Human Bioequivalence of Triprerelin Acetate for Injection

Role: collaborator

NCT06662071Recruiting

A Research Protocol for Evaluating the Efficacy of Perfused Chemotherapeutic Agents for Bladder Cancer Based on Organoid Technology

Role: collaborator

NCT06649422Not Yet Recruiting

Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study

Role: collaborator

NCT04271527Not ApplicableRecruiting

Non-inferiority Randomized Controlled Trial of Cognitive Targeted Biopsy Versus Software Targeted Biopsy

Role: collaborator

NCT05431075Phase 4Completed

Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment of Different Tetracycline Doses

Role: collaborator

NCT04305106Phase 3Unknown

Bevacizumab in Patients With Severe Covid-19

Role: collaborator

NCT05802888Phase 4Unknown

Bismuth Quadruple Therapy in Helicobacter Pylori Rescue Therapy of Different Tetracycline Doses and Frequencies.

Role: collaborator

NCT05802108Phase 4Unknown

Effect of PCSK9 Inhibitor on Retinal Microvessels in Patients With Coronary Heart Disease After Intensive Lipid-lowering Therapy

Role: lead

NCT05432115Phase 4Unknown

Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Therapy of Different Tetracycline Doses and Frequencies.

Role: collaborator

NCT05620602Unknown

The Effect of Time Intervals for Rescue Treatment on Eradication Effect of Helicobacter Pylori Infection

Role: collaborator

NCT05620589Unknown

The Effect of Time Intervals for Rescue Treatment on Eradication Effect of Helicobacter Pylori Infection

Role: collaborator

NCT05179707Unknown

A Research for Combination of Prostate Health Index (Phi) and mpMRI PI-RADS in the Diagnosis of Prostate Cancer

Role: collaborator